Orchestra BioMed Holdings, Inc. (OBIO)
| Market Cap | 253.89M |
| Revenue (ttm) | 32.72M |
| Net Income (ttm) | -54.89M |
| Shares Out | 59.88M |
| EPS (ttm) | -1.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,421,172 |
| Open | 3.900 |
| Previous Close | 3.900 |
| Day's Range | 3.900 - 4.310 |
| 52-Week Range | 2.200 - 5.424 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 12.17 (+187.03%) |
| Earnings Date | Aug 11, 2026 |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a b... [Read more]
Financial Performance
In 2025, Orchestra BioMed Holdings's revenue was $33.48 million, an increase of 1169.22% compared to the previous year's $2.64 million. Losses were -$52.96 million, -13.22% less than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price target is $12.17, which is an increase of 187.03% from the latest price.
News
Orchestra BioMed Holdings Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved and an annual frequency set for future compensation votes. No questions were raised by shareholders during the session.
Orchestra BioMed Holdings Transcript: Sidoti Small-Cap Virtual Investor Conference
Two flagship cardiovascular device therapies are advancing through pivotal trials, supported by strong partnerships with Medtronic and Terumo and robust financial backing. Key milestones include imminent BACKBEAT trial data and ongoing Virtue SAB enrollment, with commercialization targeted for 2028.
Orchestra BioMed Holdings Proxy statement: Proxy filing
Orchestra BioMed Holdings filed a proxy statement on June 16, 2026, providing details for shareholder voting and corporate governance matters.
Orchestra BioMed Holdings Transcript: Jefferies Global Healthcare Conference 2026
The session highlighted a partnership-driven model focused on R&D and pivotal trials, with major programs in hypertension therapy and drug delivery platforms. Key milestones include upcoming BackBeat trial data and Virtue enrollment completion, both with strong commercial potential and strategic partnerships.
Orchestra BioMed Holdings Slides: Corporate presentation
Orchestra BioMed Holdings has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Orchestra BioMed price target lowered to $10 from $12 at B. Riley
B. Riley lowered the firm’s price target on Orchestra BioMed (OBIO) to $10 from $12 and keeps a Buy rating on the shares. Orchestra BioMed reported Q1 results alongside key…
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patie...
Orchestra BioMed price target raised to $13 from $12 at Barclays
Barclays analyst Matt Miksic raised the firm’s price target on Orchestra BioMed (OBIO) to $13 from $12 and keeps an Overweight rating on the shares. The company’s better than expected…
Orchestra BioMed reports Q1 EPS (33c), consensus (44c)
Reports Q1 revenue $110,000, consensus $160,830. David Hochman, chairman and CEO of Orchestra BioMed (OBIO) stated, “We continued to make meaningful advancements across our late-stage cardiovascular p...
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patie...
Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline
Orchestra BioMed (OBIO) announced an update to the overall clinical and regulatory timeline for the BACKBEAT Trial evaluating Atrioventricular Interval Modulation Therapy in pacemaker-indicated patien...
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed Holdings Quarterly report: Q1 2026
Orchestra BioMed Holdings has published its Q1 2026 quarterly earnings report on May 12, 2026.
Orchestra BioMed Holdings Earnings release: Q1 2026
Orchestra BioMed Holdings released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Orchestra BioMed receives $15M payment from Ligand
Orchestra BioMed (OBIO) announced the receipt of a $15M payment from Ligand (LGND) pursuant to the previously disclosed revenue participation right purchase and sale agreement. The payment completes a...
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Mod...
Orchestra granted additional breakthrough device designation for AVIM therapy
Orchestra BioMed (OBIO) announced that the FDA has granted a second breakthrough device designation, or BDD, for AVIM therapy specific to patients with uncontrolled hypertension despite the use of ant...
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despi...
Orchestra BioMed Holdings Proxy statement: Proxy filing
Orchestra BioMed Holdings filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Orchestra BioMed Holdings Proxy statement: Proxy filing
Orchestra BioMed Holdings filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed Holdings Slides: Corporate presentation
Orchestra BioMed Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Orchestra BioMed reports FY25 EPS ($1.11), consensus ($1.74)
Reports FY25 revenue $33.482M, consensus $3.47M. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed (OBIO) stated, “We are very proud of our significant clinical, strategic and fi...